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Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and
aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic
and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in
the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer.
Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model
was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was
performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus
(VSV) and the JX-594 vaccinia virus was tested.
Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into
immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of
human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic
mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by
DNA sequencing. Spectral karyotyping revealed a largely normal diploid karyotype (in greater than 95% of cells)
with a visibly shorter chromosome 20 contig. High density SNP array analysis also revealed few genomic anomalies
in BIN-67 cells, which included loss of heterozygosity of an estimated 16.7 Mb interval on chromosome 20. SNP
array analyses of four SCCOHT samples also indicated a low frequency of genomic anomalies in the majority of
cases. Although resistant to platinum chemotherapeutic drugs, BIN-67 cell viability in vitro was reduced by >75%
after infection with oncolytic viruses.
Conclusions: These results show that SCCOHT differs from high-grade serous carcinomas by exhibiting few
chromosomal anomalies and lacking TP53 mutations. Although BIN-67 cells are resistant to standard
chemotherapeutic agents, their sensitivity to oncolytic viruses suggests that their therapeutic use in SCCOHT should
be considered.
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Ovarian small cell carcinoma of the hypercalcemic type
(SCCOHT) is a rare and highly aggressive form of ovarian
cancer first reported in 1982 by Dickerson et al. [1]. The
mean age of diagnosis is 23 years and the prognosis for
these patients is generally poor, with a two year survival of* Correspondence: bvanderhyden@ohri.ca
1Department of Cellular and Molecular Medicine, University of Ottawa, 451
Smyth Road, Ottawa, ON K1H 8M5, Canada
2Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501
Smyth Road, Ottawa, ON K1H 8L6, Canada
Full list of author information is available at the end of the article
© 2013 Gamwell et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orless than 20% [2,3]. Although not considered a familial
disease, there is a case report of an 11-year-old female
diagnosed with SCCOHT, who had a strong family history
of the disease, a reduction in the age of onset in the pro-
band, and the absence of BRCA1/BRCA2 mutations [4].
While the incidence of SCCOHT is rare in the general
population, it is the most common undifferentiated ova-
rian cancer in women under 40 years of age [5]. Its histo-
genesis is unknown, but the disease is associated with
hypercalcemia in two-thirds of patients and the frequency
of bilateral ovarian tumours is low [3]. Histologically, theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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packed epithelial cells with 80% of cases containing vari-
ably sized follicle-like structures.
The rarity and aggressiveness of SCCOHT has lent itself
poorly for study and therefore there are few reports on
therapeutic strategies and no effective treatment regimens.
While most patients undergo aggressive surgical resection
followed by multi-agent, high dose chemotherapy, very
few are cured [3]. Despite a rapid initial response to
chemotherapy and radiation therapy, recurrence rates are
high and those tumours tend to be less responsive to
chemotherapy [3,5-7].
Although SCCOHT is morphologically similar to small
cell carcinomas from other sites, its common expression of
WT1 and lack of thyroid transcription factor (TTF)-1 al-
lows it to be distinguished from other small cell cancers
[8]. Immunohistochemical characterization of 15 SCCOHT
showed frequent expression of p53, WT1 and epithelial
markers, including epithelial membrane antigen, and less
common to no expression of synaptophysin, S100 and in-
hibin [9]. The presence of p53 in 80-100% of SCCOHT
suggests that TP53 gene abnormalities may be involved in
the genesis of this highly aggressive cancer [8,9], but muta-
tional analysis has yet to be performed.
The cell line BIN-67, first reported in 1986 [10], was
established from a metastatic pelvic nodule derived from
a primary SCCOHT. In contrast to cell lines derived
from ovarian serous adenocarcinomas, the BIN-67 cells
express high levels of vimentin and respond to calcitonin
with a >20-fold increase in cAMP [10]. BIN-67 appears
to be the only SCCOHT cell line in existence and its fur-
ther characterization could improve our understanding
of this rare form of ovarian cancer. We have assayed the
tumourigenic potential of BIN-67 cells and compared
the tumours formed in a xenograft model to human
SCCOHT. We also characterized their genomic content,
performed a targeted gene mutation analysis, and tested
their sensitivity to standard chemotherapeutic agents
and to vesicular stomatitis virus (VSV) and the JX-594
vaccinia virus, both oncolytic viruses, which have been
shown to be effective novel anti-cancer treatments in a
variety of model systems [11-14].
Methods
Cell lines and SCCOHT samples
Primary mouse ovarian surface epithelial cells (MOSE)
were isolated and cultured in α-MEM supplemented with
10% fetal calf serum (FCS; Sigma Chemical Co., St Louis,
MO), epidermal growth factor and insulin-transferrin-
selenium as described [15]. The platinum-sensitive human
ovarian cancer cell line, A2780s, and its platinum-resistant
derivative, A2780cp [16], were maintained in DMEM with
10% FCS. The BIN-67 cell line was obtained from Dr. S.R.
Golding (Hospital for Special Surgery, New York) andcultured from frozen stock in DMEM supplemented with
20% FCS and enriched with 20% Ham’s F12 medium
(Sigma Chemical Co.) as previously described [10].
Samples from four SCCOHT were obtained from the
Children’s Oncology Group at Nationwide Children’s
Hospital in Columbus, Ohio, The University Health
Network (Dr. Blaise Clarke) and the Ovarian Cancer
Research Program tissue bank in Vancouver, British
Columbia, Canada. All resources provide access to sam-
ples through specific application to studies approved by
institutional review boards.
Spheroid formation assay
BIN-67 cells were tested for their ability to form spheroids
by the hanging droplet method as previously described [17].
Characterization of BIN-67 as a model of SCCOHT
BIN-67 cells (107) in 1 mL of saline were injected intraper-
itoneally into 18 female 8-week-old Fox Chase SCID mice
(CB-17 SCID, Charles Rivers Laboratories). When the
mice reached a defined endpoint (large palpable mass),
the tumours were removed, weighed and fixed in formalin.
Histologic sections (5 μm) were prepared and either
stained with hematoxylin and eosin to visualize mor-
phology or immunostained for expression of cytokeratin
(pre-diluted; Abcam, Cambridge, MA), vimentin (1:100;
Dako, Carpinteria, CA), p53 (1:50; Santa Cruz Biotechno-
logy; Santa Cruz, CA), KIT (CD117, 1:40; Dako), inhibin
(1:25; Dako), WT1 (1:100; Dako), and the markers of
neuroendocrine differentiation Pgp9.5 (1:3000; Millipore,
Billerica, MA) and α-synaptophysin (1:400; BD Transduc-
tion, Mississauga, ON).
Blood samples were collected by saphenous vein punc-
ture prior to BIN-67 xenograft and by cardiac puncture at
necropsy and serum ionized calcium levels were measured
using the i-STAT hand-held blood analyzer with EG7+
cartridges (Abbot Point of Care, Mississauga, Ontario,
Canada) to determine if tumours derived from the BIN-67
cells cause hypercalcemia.
High-density genotyping
Chromosomal anomalies in BIN-67 cells were inferred
using the Infinium™ genotyping technology with the
HumanHap300-Duo Genotyping BeadChip (Illumina, San
Diego, CA, USA) as previously described [18]. This
BeadChip contains about 318,000 genetic markers within
approximately a 5 Kb median SNP spacing. Genotyping
and imaging using BeadStudio Data Analysis software
(Illumina, San Diego, CA, USA) were performed at the
McGill University and Genome Quebec Innovation
Centre (Montreal, QC). The February 2009 human refe-
rence sequence GRCh37/hg19 assembly (genome.ucsc.
edu/cgi-bin/hgGateway) was used for the characterization
of selected intervals. SNP array data for BIN-67 is
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uk/arrayexpress/).
DNA from BIN-67 cells, four SCCOHT samples (T1,
T2, T3 and T4), and a matched normal sample from one
of the patients (T4-N) were genotyped using Affymetrix
Genome-Wide Human SNP Array 6.0 and analyzed
using CRMAv2 and HMMDosage as described previ-
ously [19,20]. To compare genomic anomalies across
samples genotyped, the analyzed data was plotted and
visualized using Circos [21].
Karyotyping
Cytogenetic preparations from BIN-67 cultures were
processed using standard methods and subjected to con-
ventional G-banding and spectral karyotype (SKY) analysis
[22]. Slides containing optimal metaphase preparations
were aged for one week at room temperature and hybrid-
ized with the SKY-painting probes (Applied Spectral
Imaging, Vista, Calif., USA) as per the manufacturer’s
instructions. Image analysis and capture were performed
using an AxioPlan Fluorescent Microscope and Spectral
Karyotyping software (Applied Spectral Imaging).
TP53, KRAS and BRAF mutation analyses
Mutation analysis of protein encoding regions and exon
splice sites regions of TP53, and commonly mutated
exons of KRAS and BRAF were sequenced and evaluated
as described previously [18].
Expression microarray analyses
Microarray expression analysis was performed using
the GeneChipW Human Genome U133 Plus 2.0 Array
(AffymetrixW, Santa Clara, CA) with total RNA from BIN-
67 cells as described previously [18]. Hybridization and
scanning were performed at the McGill University and
Genome Quebec Innovation Centre (Montreal, QC). Gene
expression levels were determined from the scanned
images using AffymetrixWMicroarray Suite (MAS) version
5.0 software expression algorithm (AffymetrixW) normal-
ized as described previously [18]. Gene expression pro-
files were compared with Affymetrix U133 Plus 2.0
(MAS5.0) generated expression profiles (similarly nor-
malized) from 10 human normal ovarian surface epithe-
lial (OSE) cell brushings available in the ArrayExpress
database (www.ebi.ac.uk/arrayexpress/), accession num-
ber E-GEOD-18520. Gene expression array data for
BIN-67 is available through the ArrayExpress Archive
(www.ebi.ac.uk/arrayexpress/).
Treatment with chemotherapeutics and oncolytic viruses
To determine the effects of chemotherapeutic drugs on
BIN-67 cells in vitro, MOSE, A2780cp, A2780s and BIN-
67 cells were plated at a density of 1 × 104 cells/100 μL
in 96-well plates and after 24 hours the drugs wereadded (cisplatin: 0, 0.1, 1, 10, 100 μg/mL; carboplatin: 0.
1, 5, 10, 100, 200 μg/mL). The numbers of viable cells
were determined 72 hours later using the CellTiter 96
AQueious cell proliferation assay system.
To determine if oncolytic viruses could infect and kill
the BIN-67 cells in vitro, the four cell lines were plated as
described above. After 24 hours, the cells were washed
twice with PBS and treated with an attenuated strain of
VSV (VSV-Δ51; multiplicity of infections (MOI): 0, 0.001,
0.01, 0.1) and the vaccinia virus JX-594 (MOI: 0, 0.001,
0.01, 0.1) in serum-free media for 72 hours. The numbers
of viable cells were determined using the metabolic
indicator dye Alamar Blue (Serotec Ltd., Raleigh, NC),
read with a Fluoroskan Ascent FL (Thermo Scientific,
Rockland, IL). Both viruses were obtained from Dr. John
Bell (Ottawa, ON) and were tagged with green fluorescent
protein (GFP) to enable assessment of infection 48 hours
after addition of virus [13,14].
Statistical analysis
Experiments were performed at least three times in trip-
licate and statistical analyses (one-way ANOVA and
Student’s t-tests) were performed using GraphPad Prism
(version 3.02; GraphPad Software, San Diego, CA).
Results
BIN-67 cells are tumourigenic
In cell culture, BIN-67 cells are small with little cytoplasm.
In hanging drop cultures, BIN 67 cells are capable of
forming densely packed spheroids with an irregular but
compact margin (Additional file 1: Figure S1), which is a
feature exhibited by some epithelial ovarian cancer cell
lines that are capable of forming tumours in mouse xeno-
graft models [17].
Intraperitoneal xenograft of the BIN-67 cells resulted
in large palpable tumours in 18/18 mice. The median
survival was 82 days (range: 61-96; Figure 1A) and the
average tumour burden was 13% of body mass (Figure 2A).
Tumours were associated with the surface of the dia-
phragm, spleen, pancreas, stomach, intestines, ovary and
uterine horn with little to no ascites production (Figure 1B).
The incidence of tumours was highest on the pancreas,
omentum and spleen and was associated with the ovary in
56% of the mice. Similar to patients with SCCOHT, BIN-
67 tumours in mice were associated with a significant in-
crease in serum ionized calcium (iCa) at endpoint (n=11)
compared with samples taken before the xenograft (n=4;
p<0.05; Figure 1C).
SCCOHT is characterized by sheet-like arrangements of
small, closely packed epithelial cells, wherein follicle-like
structures can be found [2]. H&E staining of the BIN-67
tumours revealed follicle-like structures (Figure 2B) and
small cells with scanty cytoplasm similar to the human
disease (Figure 2C,D). Histological sections showed
Figure 1 Characterization of a BIN-67 xenograft model of
SCCOHT. A) Kaplan-Meier curve showing the survival of mice
following intraperitoneal injection of BIN-67 cells. The cells form
tumours with a median survival of 82 days. B) Quantification of
tumour localization in the xenografts showed that the incidence of
tumours is highest on the pancreas, omentum and spleen and is
associated with the ovary in 56% of the mice. C) The formation of
tumours is associated with a significant increase in serum ionized
calcium (iCa) in the mice at endpoint (n=11) compared with levels
measured in samples taken before the xenograft (n=4; * p<0.05).
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ing for KIT, Pgp9.5 and p53, and sporadic staining for
cytokeratin and α-synaptophysin (Figure 2). In agreement
with primary SCCOHT cancers, there is a lack of inhibin
staining which helps to distinguish this tumour type fromgranulosa cell tumours that are typically inhibin immuno-
reactive. These observations are consistent with low ex-
pression values for KIT, UCHL1 (Pgp9.5), TP53, and INHA
(inhibin α) in contrast to higher levels of expression of VIM
and WT1 as determined using gene expression microarray
analyses (Additional file 2: Figure S2).
BIN-67 and SCCOHT exhibit low level chromosomal
anomalies
SKY analysis of BIN-67 cells revealed a predominantly
diploid (46,XX) cell population (>95% of cells), and a
sub-population of tetraploid (92, XXXX) cells. The cells
show a normal karyotype with the exception of a visibly
shorter chromosome 20 contig, which was evident from
both SKY analysis and Giemsa staining (Figure 3).
High-density SNP array analyses based on the Infinium™
HumanHap300-Duo BeadChip was used to further cha-
racterize genomic anomalies in BIN-67 cells (Figure 4). As
summarized in Table 1, nine discrete copy number varia-
tions were detected ranging in size from approximately 97
Kb to 16.8 Mb. Copy number gain involved 2p12, 4q25,
5p13.3-p13.2, 16q23.1, and 21q22.12, and copy number
loss involved 3q13.32, 4q22.1, and 20q11.22-q13.2. Loss of
heterozygosity was detectable with the extensive region of
copy number loss overlapping 20q11.22-q13.2. This obs-
ervation along with karyotype analysis (Figure 3) suggests
that this chromosome had undergone an intrachromo-
somal deletion.
To compare genomic landscapes, Affymetrix SNP 6.0
array analysis was performed on the BIN-67 cells and
four SCCOHT samples: T1, T2, T3 and T4, and one
matched normal sample (T4-N). A summary of the copy
number variations is shown aligned to chromosomal
position, displayed in a Circos plot in Figure 5. Discrete
copy number variations were observed with all samples.
Sample T4 was notable for exhibiting the largest number
of genomic variations. Notable is that SNP array results
of BIN-67 cells were concordant with that derived using
the Infinium platform. Though the large 20q11.22-q13.2
deletion observed in BIN-67 was not detectable in any
of the tumour specimens, there were many discrete
anomalies (both gains and losses) that overlapped similar
regions in the tumour samples and the BIN-67 sample
that were not observed in the reference normal sample,
suggesting that they may be unique to the development
of SCCOHT. In total the BIN-67 sample had 100
discrete gains or losses, with 90 of these not found in
the normal sample. Of these 90 gains or losses, 34 were
found in at least one of the tumour samples, and one
loss (chromosome 1; 151028548-151035325) was shared
by all 4 tumour samples but not with the normal sample.
Examples of some shared copy number variations
are summarized in Additional file 3: Table S1 and the
Figure 2 Histology and expression of protein markers in BIN-67 tumours. A) BIN-67 cells form large tumours in SCID mice. B-D) H&E
staining of the tumours indicates that the histology resembles human small cell ovarian cancers, with homogeneous sheets of small cells and
follicle-like structures (B). E-L) Immunohistochemical staining for cytokeratin, α-synaptophysin, KIT, Pgp9.5, vimentin, inhibin, p53 and WT-1. B: 10X;
C, I-L: 20X; D-H: 40X.
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HMMDosage analysis can be found in Additional file 4:
Table S2.
BIN-67 mutational spectra exclude conventional genes
A sequence analysis was performed to determine if
BIN-67 harboured mutations in TP53, KRAS and BRAF
genes previously shown mutated in epithelial ovarian
carcinomas [18]. Mutation analysis did not detect anyvariants in the protein coding regions of TP53 nor in
commonly mutated exons of KRAS and BRAF.
Gene expression profile targeted genomic regions
affected in BIN-67
Transcriptome analysis of BIN-67 proved to be a chal-
lenge as there is no corresponding normal tissue avail-
able for comparison. We therefore focused our analysis
Figure 3 Spectral karyotype analysis of BIN-67 cells. Spectral
karyotype analysis of BIN-67 cells exhibiting normal diploid
population with the exception of a shorter chromosome 20 contig
shown with an arrow (A) and Giemsa stained image of
chromosome 20 contigs, which also show an abnormally shortened
contig as shown with an arrow (B).
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within regions exhibiting copy number gains, as these
regions may contain genes exhibiting increased expres-
sion due to alterations in copy number as demonstrated
in our previous analyses of ovarian cancer cell lines
exhibiting distinct genomic amplification events [23],
(Table 1). Although the cell type of origin of SCCOHT
is not known, we compared the expression profiles to
publicly available data representing OSE samples derived
using the same gene expression microarray platform.
Only genes mapping to the 4q25 and 5p13.3-p13.2
exhibited evidence of expression greater than 2-fold
when compared with OSE samples (Additional file 5:
Figure S3). Of the three genes ALPK1, NEUROG2,
and LARP7 exhibiting higher levels of expression in the
4q25 region, only ALPK1 and NEUROG2 consistently
exhibited greater than 2-fold levels of expression when
compared with each OSE sample. Of 5 of 28 genes that
map to the 5p13.3-p13.2 region and exhibit greater than
2-fold difference in gene expression, only PDZD2, SUB1,
PRLR and SKP2 consistently exhibited expression greater
than 2-fold in two-way comparisons to each OSE sample
(Additional file 5: Figure S3).Treatment with standard chemotherapeutics and
oncolytic viruses
The high mortality of women with SCCOHT indicates a
strong need to improve the current strategies for treat-
ment. To investigate the response of BIN-67 cells to
standard and novel treatments, we first examined the ef-
fect of carboplatin and cisplatin on BIN-67 viability. As
controls, chemosensitive A2780s cells and chemoresistant
A2780cp cells confirmed their differential sensitivity to
carboplatin at concentrations of 5 and 10 μg/mL, with less
than 25% viability for both cell lines at higher concentra-
tions (Figure 6A). The normal MOSE cells remained vi-
able (>70%) after exposure to concentrations up to 10 μg/
mL, but viability was reduced at higher concentrations. In
contrast, BIN-67 cells were exceptionally resistant, with
61% viability at the highest concentration of carboplatin
tested (Figure 6A) and similar resistance to cisplatin-
induced cell killing (Figure 6B). BIN-67 cells proved to be
resistant to a non-platinum drug as well, with cell viability
reduced to 64% after 72 hours of exposure to 10 μM taxol,
compared with only 22% of A2780cp cells remaining vi-
able (data not shown).
Since BIN-67 cells were resistant to conventional che-
motherapeutics, we tested their response to novel treat-
ments. Two oncolytic viruses, the vaccinia virus JX-594
and VSV, were tested for cytotoxic effects on the four
cell lines. Treatment with GFP-tagged viruses showed
that BIN-67 cells could be readily infected with both of
these viruses (Additional file 6: Figure S4). Infection with
JX-594 significantly reduced BIN-67 cell viability at an
MOI of 0.01, and this viability was reduced further to
just 20% when the cells were exposed to an MOI of 0.1.
The sensitivity of BIN-67 to JX-954 was greater than the
response of the A2780s and A2780cp cells, whereas nor-
mal MOSE remained unaffected (Figure 6C). BIN-67
cells were also very sensitive to VSV-induced cell killing,
with a significant (75%) decrease in viability evident at
an MOI of 0.001, and just 7% cell viability at the higher
MOIs (Figure 6D).
Discussion
Small cell carcinoma is a rare tumour that is usually
associated with the lung and/or cervix in females, but
can occur rarely in the ovary. The biology of SCCOHT
is poorly understood, but the relatively young age of
SCCOHT patients and the difficulties associated with
treating them warrant investigation of this very aggres-
sive type of cancer. Given the challenges of studying the
rare forms of cancer in humans, we have established and
characterized a unique xenograft model of SCCOHT.
Validation of this model was achieved by demonstrating
its similarity to the human disease in its histological and
immunohistochemical features, as well as the exhibition of
hypercalcemia, which occurs in the majority of SCCOHT
Figure 4 Illumina BeadChip array analysis of BIN-67. The results for each marker (SNP) are shown aligned to its genomic position along a
chromosome (Mb). The top image for each panel contains the B allele frequency (zygosity) and bottom image the Log R ratio (copy number) for
each marker analyzed. Data is absent for centromeric regions as these regions are not represented by SNP arrays. Gains or losses (gray shaded
regions) were observed for all chromosomes indicated with the exception of chromosome 17.
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in hanging drop cultures also has been observed in epi-
thelial ovarian cancer cell lines that are tumourigenic in
mouse xenograft models [17]. Though the factors involved
are not known, comparative transcriptome analyses of
epithelial ovarian cancer cell line models have shown that
spheroids and tumour xenografts were more similar in
their expression profiles than when compared withtranscriptomes derived from cell lines grown as mono-
layers in cultures [17,24]. Notable also is that suppression
of tumourigenic potential in at least one ovarian cancer
cell line resulted in loss of both spheroid forming capacity
and ability to form mouse tumour xenografts [24]. The
growth phenotypes exhibited by BIN-67 will enable
further study of this unique model of SCCOHT to address
progression and treatment of this disease.
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C20orf173, ERGIC3, FER1L4, SPAG4, CPNE1, RBM12, NFS1, ROMO1, RBM39,
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SEMG2, SLPI, MATN4, RBPJL, SDC4, SYS1, SYS1-DBNDD2, TP53TG5,
DBNDD2, PIGT, WFDC2, SPINT3, WFDC6, SPINLW1-WFDC6, SPINLW1,
WFDC8, WFDC9, WFDC10A, WFDC11, WFDC10B, WFDC13, SPINT4, WFDC3,
DNTTIP1, UBE2C, TNNC2, SNX21, ACOT8, ZSWIM3, ZSWIM1, C20orf165,
NEURL2, CTSA, PLTP, PCIF1, ZNF335, MMP9, SLC12A5, NCOA5, CD40,
CDH22, SLC35C2, ELMO2, MKRN7P, LOC100240726, ZNF334, C20orf123,
SLC13A3, TP53RK, SLC2A10, EYA2, , ZMYND8, LOC100131496, NCOA3,
SULF2, LOC284749, PREX1, ARFGEF2, CSE1L, STAU1, DDX27, ZNFX1,
NCRNA00275, , KCNB1, PTGIS, B4GALT5, SLC9A8, SPATA2, RNF114, SNAI1,
TMEM189-UBE2V1, UBE2V1, TMEM189, CEBPB, LOC284751, PTPN1,
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Figure 5 Circos plot of Affymetrix SNP array analysis performed on the BIN-67 cells and four SCCOHT samples. The track order (outside
in) is patient tumour sample T2, BIN-67, patient tumour samples T1, T3, T4 and the matched normal sample, T4-N.
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tumours revealed a diagnostic expression pattern that
is similar to that reported in humans, notably intense
expression of WT-1 and vimentin and lack of expression
of inhibin. The moderate levels of staining for p53 and
KIT also resemble human cancers [8,9]. In agreement
with the 90% of human SCCOHT tumours that are im-
munoreactive for cytokeratins [5], we observed cytokeratin
staining in the BIN-67 tumours, when detected using
pan-cytokeratin antibodies. The limited, sporadic staining
for α-synaptophysin was also as expected, since this is a
neuroendocrine marker and is not often found in human
SCCOHT [9].
Small cell carcinomas of the ovary are distinguished
into two types: hypercalcemic and pulmonary type
(SCCOPT). SCCOPT are so designated because of their
similarities to small cell carcinomas of the lung [2].
SCCOHT differ markedly from SCCOPT and from small
cell lung cancers in clinical presentation, histological fea-
tures and immunohistochemical markers. Small cell car-
cinomas of the lung and cervix are often associated with
neuroendocrine differentiation as manifested by their
histologic growth pattern, ultrastructure and expression
of neuroendocrine markers, whereas the current consen-
sus is that SCCOHT are not neuroendocrine in type [2].
The moderate staining for PGP9.5, a neuroendocrinemarker, in the BIN-67 tumours was therefore unex-
pected. PGP9.5 (UCHL-1) is a neurospecific peptide
that functions to remove ubiquitin from ubiquitinated
proteins and prevents them from targeted degradation
by proteasomes. It is abundantly expressed in small cell
lung and cervical cancers [25,26], which are both neuro-
endocrine tumours. To our knowledge, the expression of
PGP9.5 has not previously been examined in SCCOHT,
and so it remains unclear whether its expression in the
BIN-67 tumours is an unanticipated feature of this type
of tumour or whether xenografting these cells had modi-
fied their behaviour.
Known as a paraneoplastic disorder, humoral hypercal-
cemia presents in a variety of cancers, including squamous
cell carcinoma of lung, adenocarcinoma of gastrointestinal
tract, and small cell carcinoma of ovary. The hypercal-
cemia may be caused by the secretion of parathyroid
hormone related protein (PTHrp) by the tumour cells,
which can act through PTH receptors to mediate the cal-
cium release [27-30]. The hypercalcemia observed in the
mice with BIN-67-derived tumours therefore reflects well
the hypercalcemia that occurs in the majority of patients
with SCCOHT.
BIN-67 lacks the mutational spectrum characteristic of
the major histopathological subtypes of ovarian cancer.
The low level of chromosomal anomalies and absence of
Figure 6 Cell viability of MOSE, A2780s, A2780cp and BIN-67 cells after treatment with chemotherapeutics and oncolytic viruses. Cell
viability of MOSE, A2780s, A2780cp and BIN-67 cells after treatment for 72 hours with carboplatin (A), cisplatin (B), the vaccinia virus JX-594 (C)
and VSV (D) at the concentrations/MOIs indicated. Viability was assessed using MTS assays, and bars show mean ± SEM of viable cells with data
normalized to 100% for untreated cells. Bars indicated with an asterisk identify treatment groups that are significantly different from MOSE cells at
that same concentration/MOI (p<0.05).
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grade ovarian serous carcinomas [31,32]. The absence of
KRAS/BRAF mutation also distinguishes BIN-67 from
low-grade ovarian serous carcinomas and mucinous
cancers [33,34]. The low level of chromosomal anomal-
ies was also observed with three of the four SCCOHT,
suggesting that a modest alteration in genomic land-
scape may be characteristic of this type of cancer. One
genomic anomaly was common to all four SCCOHT
patient tumour samples and the BIN-67 cells, but not
the matched normal sample. This loss occurred in the
region of chromosome 1 containing the MLLT11 gene
(myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 11), making this a
potentially interesting gene to study in SCCOHT.
MLLT11, also known as AF1Q, has been reported tobe an oncogenic factor involved in the development of
leukemia and thyroid tumours, and breast cancer metas-
tasis [35-37].
The 5p13.3-p13.2 interval gained in BIN-67 has been
shown to be amplified in various cancer types, including
ovarian cancer [31]. Although various amplicons have
been described, PDZD2, GOLPH3, PRLR and SKP2 have
emerged as potential targets, which is interesting given
their gene expression profile in BIN-67 cells. PDZD2 may
be involved in intracellular signaling and is overexpressed
in prostate cancer and associated with the initiation or
early events in tumourigenesis [38]. Paradoxically, it has
recently been shown to induce either senescence or apop-
tosis in cancer cells via transcriptional activation of TP53
[39]. GOLPH3, which encodes a peripheral membrane
protein of the Golgi stack and may have a regulatory
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growth-factor-induced mTOR signaling and consequently
alter response to rapamycin, an mTOR inhibitor, in cancer
cells [40]. Further investigation of BIN-67 cells for sensi-
tivity to rapamycin is warranted given the potential of
identifying new targets for chemotherapy as this drug is in
clinical use.
PRLR encodes the prolactin receptor, which may
function to modulate endocrine and autocrine effects of
prolactin in normal and cancer tissues, and has been
extensively studied as a potential therapeutic target in
breast cancer [reviewed in 41]. It was recently shown to be
associated with increasing survival and migration of ovar-
ian cancer cells and was proposed as a potential thera-
peutic target for receptor antagonists for ovarian cancer
[42]. Although PDZD2 and GOLPHA3 are potential tar-
gets of amplification in BIN-67, SKP2, which encodes a
member of the F-Box protein family S-phase kinase-
associated protein 2 (p45), is an established oncogene, and
has been extensively studied as a therapeutic target [43].
SKP2 protein overexpression in epithelial ovarian cancers
has been reported [44,45] and this expression signature
has been proposed as a prognostic factor [46,47].
The gain of the 4q25 interval in BIN-67 is interesting,
as it contains LARP7, which encodes PIP7S, recently
shown to bind and stabilize all the nuclear 7SK RNA
leading to inactivation of a general transcription factor
P-TEFb that stimulates RNA polymerase II elongation
and cotranscriptional processing of pre-mRNA [48].
Knockdown of PIP7S with shRNA in a normal human
mammary epithelial cell line shifts the P-TEFb equilib-
rium and causes disrupted epithelial differentiation, P-
TEFb-dependent malignant transformation and activa-
tion of key tumour-related genes, which is consistent
with the tumour suppressor function of its Drosophila
homolog [49].
The prognosis of women with SCCOHT is very poor,
largely due to the lack of effective treatments; however,
there have been some case reports of long-term survival
with a multi-modality approach to treatment. Tewari et al.
[50] reported a case of SCCOHT diagnosed during preg-
nancy that was treated with cytoreductive surgery and
multi-agent chemotherapy (vinblastine, cisplatin, cyclo-
phosphamide, bleomycin, doxorubicin, and etoposide). The
patient was alive and without evidence of disease 5.5 years
after diagnosis. Treatment with conservative surgery and
the same chemotherapy agents resulted in a 19 year old pa-
tient with advanced-stage (Stage IIIC) SCCOHT doing well
more than 2 years after completion of treatment [51]. A
more recent multi-national retrospective analysis of the
management of 17 SCCOHT patients resulted in the rec-
ommendation of multi-modality treatment approaches in-
cluding surgery and chemotherapy with the addition of
radiotherapy either sequentially or concurrently [52].Despite these reports, the prognosis and outcome for
the majority of patients diagnosed with SCCOHT remains
poor and better treatment options are needed. Oncolytic
virus therapy is an innovative alternative to conventional
cancer therapies and is based on the concept that it is
possible to select or engineer viruses to preferentially rep-
licate in and kill tumour cells [11,53-55]. This cancer cell
selectivity is at least in part due to an acquired, tumour-
specific defect in cellular innate antiviral responses [56].
Oncolytic vaccinia viruses are currently positioned for
testing in Phase III clinical trials [13] and VSV is a proto-
typical rhabdovirus that grows poorly in normal tissues
but replicates efficiently in cells lacking an intact IFN re-
sponse [57]. Both oncolytic viruses efficiently infected the
BIN-67 cells, resulting in a loss of cell viability by as much
as 93%. In contrast, BIN-67 cells showed marked resist-
ance to carboplatin, cisplatin and taxol, chemotherapeutic
agents commonly used for the treatment of ovarian can-
cer. This resistance was greater than that shown by the
A2780cp cells, an epithelial ovarian cancer cell line com-
monly used to study the mechanisms of chemoresistance.
These results suggest that platinum drugs may not be the
optimal treatment for SCCOHT and that therapeutic use
of oncolytic viruses should be investigated further for the
treatment of SCCOHT, as well as other ovarian cancers.
Conclusions
Although the establishment of other SCCOHT-derived
cell lines has been periodically reported [58,59], it ap-
pears that none have been investigated beyond the initial
reports. The demonstration that BIN-67 cells can form
spheroids in vitro and tumours in vivo provide two novel
model systems with potential value for preclinical drug
screening. Spheroid models have been shown to better
mimic the in vivo tumour gene expression patterns than
monolayer cultures, as have been demonstrated in com-
parative transcriptome profiling analyses [17,24]. BIN-67
cells therefore provide the rare opportunity to investi-
gate the biology of SCCOHT cells and tumours. Further
characterization of this rare form of ovarian cancer may
help to determine the origins of this disease as well as
increase the number of therapeutic options.Additional files
Additional file 1: Figure S1. Morphological appearance of spheroids in
hanging droplets cell culture assays four or five days after seeding BIN-67
cells in growth medium (20x magnification).
Additional file 2: Figure S2. Affymetrix microarray gene expression
values of selected probe sets representing genes examined by
immunohistochemistry analysis in tumour xenografts of BIN-67 cells.
Additional file 3: Table S1. Examples of SNPs shared between BIN-67
and at least 1 tumour sample, but not the matched normal sample
identified by CRMAv2 and HMMDosage analysis of the Affymetrix
Genome-Wide Human SNP Array 6.0.
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http://www.ojrd.com/content/8/1/33Additional file 4: Table S2. Complete Affymetrix Genome-Wide
Human SNP Array 6.0 CRMAv2 and HMMDosage analysis results.
Additional file 5: Figure S3. Affymetrix microarray gene expression
values of probe sets representing genes exhibiting at least a two-fold
increased expression in BIN-67 cells relative to mean of 10 OSE samples.
The differentially expressed genes map within the 4q24 and 5p13.3-p13.2
intervals exhibiting increased copy number as inferred by Illumina
BeadArray genotyping analysis.
Additional file 6: Figure S4. BIN-67 cell infection by VSV (Figure S4A)
and vaccinia virus JX-594 (Figure S4B). BIN-67 cells were compared with
A2780s and A2780cp ovarian cancer cell lines and normal MOSE for their
susceptibility to infection by GFP-tagged virus. After 48 hours of infection,
BIN-67 cells were found to express GFP after exposure to all MOI,
indicating that these cells were as readily infected with VSV as the two
other cancer cell lines. At this time, the cells already display a rounded
and detached morphology, suggestive of cells undergoing cell death.
Normal MOSE cells were more resistant to infection by VSV and JX-594.
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